The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: 0.00 (0.00%)
Spread: 0.40 (0.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 120.40
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Syncona confident after Q1 market volatility

Tue, 16th Aug 2022 10:06

(Sharecast News) - Healthcare investor Syncona reported net assets of £1.33bn at the end of its first quarter on Tuesday, or 197.9p per share, up from £1.31bn and 194.4p per share at the end of March.

The FTSE 250 company said that made for a net asset value return of 1.8% in the three months ended 30 June, driven by the positive impact of foreign exchange across the portfolio and capital pool.

Its life science portfolio was valued at £561.8m, up from £524.9m, with a return of -0.2% in the quarter.

The share prices of Syncona's listed holdings were still being negatively impacted by market volatility, although the board said it remained "confident" in the fundamentals of its companies.

It added that the portfolio remained funded to deliver on upcoming clinical milestones in the 2023 financial year, with £38m deployed in the period and a capital base of £768.7m as at 30 June, down from £784.9m at the end of March.

The company said that capital base provided it with a strategic advantage, as it looked to fund "exciting" new opportunities while supporting its current portfolio.

"We are pleased with the continued progress across the Syncona portfolio during the quarter, with our companies delivering on a number of operational and clinical milestones," said Martin Murphy, chair and chief executive officer at Syncona Investment Management.

"Our strategic capital base remains a key competitive advantage, enabling us to continue to fund our companies through the current market conditions, with £38m of capital deployed in the quarter, and strongly positioning us to take advantage of exciting opportunities to found new Syncona companies."

Murphy said Syncona was founded with a long-term vision and approach to leverage its experience in managing life science companies through all market cycles.

"We are confident that we can navigate the current environment to deliver strong risk-adjusted returns for our shareholders and fulfil our purpose to extend and enhance human life."

At 0940 BST, shares in Syncona were down 0.2% at 199.2p.

Reporting by Josh White at Sharecast.com.

More News
17 Jun 2021 08:56

Syncona gets boost in full-year from life science portfolio

Syncona gets boost in full-year from life science portfolio

Read more
17 Jun 2021 07:46

Syncona reports positive asset value return in final results

(Sharecast News) - Healthcare investment company Syncona reported year-end net assets of £1.3bn in its final results on Thursday, up from £1.25bn in the prior year.

Read more
10 Jun 2021 16:09

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
18 May 2021 15:54

IN BRIEF: Syncona investee Freeline posts widened first quarter loss

IN BRIEF: Syncona investee Freeline posts widened first quarter loss

Read more
7 May 2021 16:58

LONDON MARKET CLOSE: Equities rally after shocking US jobs undershoot

LONDON MARKET CLOSE: Equities rally after shocking US jobs undershoot

Read more
7 May 2021 12:13

LONDON MARKET MIDDAY: FTSE 100 hits 14-month high ahead of US jobs

LONDON MARKET MIDDAY: FTSE 100 hits 14-month high ahead of US jobs

Read more
7 May 2021 09:23

Syncona investee Gyroscope postpones US IPO citing "market conditions"

Syncona investee Gyroscope postpones US IPO citing "market conditions"

Read more
7 May 2021 07:31

Syncona's Gyroscope Therapeutics postpones IPO

(Sharecast News) - Syncona portfolio company Gyroscope Therapeutics Holdings has postponed plans for its initial public offering in light of current market conditions, the healthcare firm said on Friday.

Read more
4 May 2021 10:25

Syncona's Gyroscope Therapeutics progressing towards US float

Syncona's Gyroscope Therapeutics progressing towards US float

Read more
19 Apr 2021 09:53

Syncona's Gyroscope Therapeutics files for potential US IPO

Syncona's Gyroscope Therapeutics files for potential US IPO

Read more
6 Apr 2021 17:26

IN BRIEF: Syncona director and CIO sell GBP1.6 million in shares

IN BRIEF: Syncona director and CIO sell GBP1.6 million in shares

Read more
1 Apr 2021 12:00

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Read more
31 Mar 2021 09:18

Syncona says Achilles stake leaps to GBP145 million value after IPO

Syncona says Achilles stake leaps to GBP145 million value after IPO

Read more
31 Mar 2021 07:41

Achilles Therapeutics prices IPO at $175m as Syncona keeps 27% stake

(Sharecast News) - Syncona portfolio biopharma company Achilles Therapeutics said its US initial public offering (IPO) will raise $175.5m (£127.8mln).

Read more
30 Mar 2021 16:01

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.